Explore the latest in Drug Target Binding and Potency Assays! ??
Did you miss our SelectScience webinar on our brand-new biosensor, the heliXcyto???
Not to worry, we asked our Director of Biophysics Dr Nichole Cerutti to write a blog about heliXcyto's single-cell Interaction Cytometry (scIC) capabilities.
Understanding how drugs bind to their biological targets is essential to effective therapeutic development. Learn more about how techniques like scIC and SPR are helping drug developers to understand binding kinetics.
Building your Bioassay with Quantics Biostatistics ??
Our CEO Andy Upsall and Scientific Director of Bioanalytical Dr Andrew Baron, have teamed up with Quantics Biostatistics for our latest blog series, Building your Bioassay.?
Bioassays are pivotal in the development of safe and effective biotherapeutics. Our first blog covers the wide applications of bioassays, starting with the most important – the potency assay.
Looking forwards to 2025 ??
As this year's conference calendar draws to a close, we're looking forward to attending the biggest events in immunology in 2025. So far, we're scheduled to attend:
We're excited to be state-side, showcasing our immuno-oncology capabilities.?
Share your thoughts and leave us feedback! ??
Is there anything you would you like to see in our newsletter in the future? Please email your thoughts and suggestions to [email protected].
Best wishes,
The RoukenBio Team.
Facilitating scientist to scientist support outsourcing innovative immunological assays. Making it simpler for our customers to succeed.
3 个月Excited by what 2025 already promises to bring to our customers at RoukenBio (new innovative services and access to additional in real life touch points).